Clinical Trial Update: A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

View source ↗

Summary

This clinical trial update describes a study evaluating guselkumab and an interleukin-17 (IL-17) inhibitor in psoriatic arthritis in routine clinical practice.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Guselkumab (guselkumab)
• Interleukin-17 inhibitor

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Arthritis, Psoriatic | Status: ACTIVE_NOT_RECRUITING